Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Darrell J. White,Michael J. Kovacs,Andrew Belch,Keith Stewart,Christine Chen,Sheldon Rubin,David A. Macdonald,Erica Harnett,Judy-Anne W. Chapman,Lois E. Shepherd,Ralph M. Meyer

Blood（2007）

引用 0|浏览0

暂无评分

摘要

Introduction. The NCIC CTG is conducting phase II testing to establish the tolerability and estimate the efficacy of combining lenalidomide (L) + melphalan (M) over multiple cycles for previously untreated patients with multiple myeloma who are ineligible for stem cell transplantation. We report the data from the preliminary safety phase of this trial.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要